Pharma Mar, S.A. (BME:PHM)
Spain flag Spain · Delayed Price · Currency is EUR
66.60
-0.65 (-0.97%)
Nov 16, 2026, 5:35 PM CET

Pharma Mar Statistics

Total Valuation

Pharma Mar has a market cap or net worth of EUR 1.15 billion. The enterprise value is 1.05 billion.

Market Cap1.15B
Enterprise Value 1.05B

Important Dates

The last earnings date was Thursday, October 29, 2026.

Earnings Date Oct 29, 2026
Ex-Dividend Date Jul 8, 2026

Share Statistics

Pharma Mar has 17.34 million shares outstanding.

Current Share Class 17.34M
Shares Outstanding 17.34M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 12.06%
Owned by Institutions (%) 12.15%
Float 13.40M

Valuation Ratios

The trailing PE ratio is 16.89 and the forward PE ratio is 15.53. Pharma Mar's PEG ratio is 0.74.

PE Ratio 16.89
Forward PE 15.53
PS Ratio 4.86
PB Ratio 4.87
P/TBV Ratio 4.96
P/FCF Ratio 26.00
P/OCF Ratio 21.87
PEG Ratio 0.74
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.93, with an EV/FCF ratio of 23.61.

EV / Earnings 15.33
EV / Sales 4.42
EV / EBITDA 17.93
EV / EBIT 20.77
EV / FCF 23.61

Financial Position

The company has a current ratio of 2.36, with a Debt / Equity ratio of 0.30.

Current Ratio 2.36
Quick Ratio 1.83
Debt / Equity 0.30
Debt / EBITDA 1.20
Debt / FCF 1.58
Interest Coverage 69.72

Financial Efficiency

Return on equity (ROE) is 31.47% and return on invested capital (ROIC) is 39.05%.

Return on Equity (ROE) 31.47%
Return on Assets (ROA) 8.41%
Return on Invested Capital (ROIC) 39.05%
Return on Capital Employed (ROCE) 17.83%
Weighted Average Cost of Capital (WACC) 6.31%
Revenue Per Employee 470,091
Profits Per Employee 135,384
Employee Count505
Asset Turnover 0.63
Inventory Turnover 0.30

Taxes

Income Tax -15.34M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -11.96% in the last 52 weeks. The beta is 0.44, so Pharma Mar's price volatility has been lower than the market average.

Beta (5Y) 0.44
52-Week Price Change -11.96%
50-Day Moving Average 70.66
200-Day Moving Average 81.27
Relative Strength Index (RSI) 43.07
Average Volume (20 Days) 40,147

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Pharma Mar had revenue of EUR 237.40 million and earned 68.37 million in profits. Earnings per share was 3.94.

Revenue237.40M
Gross Profit 221.56M
Operating Income 50.48M
Pretax Income 53.03M
Net Income 68.37M
EBITDA 56.55M
EBIT 50.48M
Earnings Per Share (EPS) 3.94
Full Income Statement

Balance Sheet

The company has 176.29 million in cash and 70.07 million in debt, with a net cash position of 106.23 million or 6.13 per share.

Cash & Cash Equivalents 176.29M
Total Debt 70.07M
Net Cash 106.23M
Net Cash Per Share 6.13
Equity (Book Value) 237.00M
Book Value Per Share 13.67
Working Capital 170.18M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 52.80 million and capital expenditures -8.39 million, giving a free cash flow of 44.41 million.

Operating Cash Flow 52.80M
Capital Expenditures -8.39M
Depreciation & Amortization 6.08M
Net Borrowing 16.58M
Free Cash Flow 44.41M
FCF Per Share 2.56
Full Cash Flow Statement

Margins

Gross margin is 93.33%, with operating and profit margins of 21.26% and 28.80%.

Gross Margin 93.33%
Operating Margin 21.26%
Pretax Margin 22.34%
Profit Margin 28.80%
EBITDA Margin 23.82%
EBIT Margin 21.26%
FCF Margin 18.71%

Dividends & Yields

This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 1.50%.

Dividend Per Share 1.00
Dividend Yield 1.50%
Dividend Growth (YoY) 25.00%
Years of Dividend Growth 1
Payout Ratio 25.35%
FCF Payout Ratio 39.04%
Buyback Yield n/a
Shareholder Yield 1.50%
Earnings Yield 5.92%
FCF Yield 3.85%
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Analyst Forecast

The average price target for Pharma Mar is 98.94, which is 48.56% higher than the current price. The consensus rating is "Buy".

Price Target 98.94
Price Target Difference 48.56%
Analyst Consensus Buy
Analyst Count 8
Revenue Growth Forecast (3Y) 16.99%
EPS Growth Forecast (3Y) 21.87%

Stock Splits

The last stock split was on July 22, 2020. It was a reverse split with a ratio of 0.0833333333.

Last Split Date Jul 22, 2020
Split Type Reverse
Split Ratio 0.0833333333

Scores

Pharma Mar has an Altman Z-Score of 7.29 and a Piotroski F-Score of 5.

Altman Z-Score 7.29
Piotroski F-Score 5